Clinical Trial Update: A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis [Phase 3]

View source ↗

Summary

An update on Amgen's Phase 3, double-blind, placebo-controlled trial of rocatinlimab for prurigo nodularis, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prurigo Nodularis

Drugs mentioned

• Rocatinlimab (rocatinlimab)

Snippet

Sponsor: Amgen | Conditions: Prurigo Nodularis | Phase 3 | Status: ACTIVE_NOT_RECRUITING